Quest Diagnostics (NYSE:DGX) PT Raised to $155.00 at Mizuho

Quest Diagnostics (NYSE:DGX) had its price target upped by research analysts at Mizuho from $150.00 to $155.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the medical research company’s stock. Mizuho’s price objective suggests a potential upside of 13.35% from the company’s current price.

Several other research firms have also issued reports on DGX. Barclays began coverage on shares of Quest Diagnostics in a report on Wednesday, January 3rd. They set an “equal weight” rating and a $145.00 target price for the company. Truist Financial reiterated a “hold” rating and set a $145.00 target price on shares of Quest Diagnostics in a report on Wednesday, March 20th. TheStreet lowered shares of Quest Diagnostics from a “b-” rating to a “c” rating in a report on Monday, February 5th. SVB Leerink began coverage on shares of Quest Diagnostics in a report on Monday, February 26th. They set a “market perform” rating and a $135.00 target price for the company. Finally, Jefferies Financial Group upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating and lifted their target price for the company from $140.00 to $155.00 in a report on Wednesday, February 7th. Ten research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $145.08.

Quest Diagnostics Stock Performance

Shares of DGX opened at $136.74 on Wednesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.31 and a quick ratio of 1.20. Quest Diagnostics has a one year low of $119.59 and a one year high of $148.62. The company has a 50-day simple moving average of $128.50 and a two-hundred day simple moving average of $131.03. The firm has a market capitalization of $15.19 billion, a PE ratio of 18.26, a price-to-earnings-growth ratio of 2.81 and a beta of 0.91.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.15 EPS for the quarter, topping the consensus estimate of $2.11 by $0.04. Quest Diagnostics had a net margin of 9.23% and a return on equity of 15.79%. The business had revenue of $2.29 billion during the quarter, compared to analyst estimates of $2.25 billion. During the same period last year, the business posted $1.98 earnings per share. Quest Diagnostics’s quarterly revenue was down 1.9% compared to the same quarter last year. On average, analysts anticipate that Quest Diagnostics will post 8.75 EPS for the current fiscal year.

Insider Activity at Quest Diagnostics

In other Quest Diagnostics news, EVP Catherine T. Doherty sold 821 shares of Quest Diagnostics stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $126.14, for a total value of $103,560.94. Following the completion of the sale, the executive vice president now owns 70,800 shares of the company’s stock, valued at approximately $8,930,712. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Quest Diagnostics news, SVP Michael E. Prevoznik sold 661 shares of Quest Diagnostics stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $126.14, for a total value of $83,378.54. Following the completion of the sale, the senior vice president now owns 40,206 shares of the company’s stock, valued at approximately $5,071,584.84. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Catherine T. Doherty sold 821 shares of Quest Diagnostics stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $126.14, for a total transaction of $103,560.94. Following the transaction, the executive vice president now owns 70,800 shares in the company, valued at approximately $8,930,712. The disclosure for this sale can be found here. Insiders sold 15,150 shares of company stock valued at $1,913,202 over the last 90 days. Corporate insiders own 0.79% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Czech National Bank boosted its stake in shares of Quest Diagnostics by 0.4% during the 4th quarter. Czech National Bank now owns 19,692 shares of the medical research company’s stock worth $2,715,000 after acquiring an additional 75 shares during the last quarter. Mendota Financial Group LLC lifted its stake in shares of Quest Diagnostics by 6.2% during the 4th quarter. Mendota Financial Group LLC now owns 1,296 shares of the medical research company’s stock valued at $179,000 after buying an additional 76 shares in the last quarter. Exchange Traded Concepts LLC lifted its stake in shares of Quest Diagnostics by 1.9% during the 3rd quarter. Exchange Traded Concepts LLC now owns 4,417 shares of the medical research company’s stock valued at $538,000 after buying an additional 84 shares in the last quarter. Montecito Bank & Trust lifted its stake in shares of Quest Diagnostics by 4.7% during the 4th quarter. Montecito Bank & Trust now owns 1,909 shares of the medical research company’s stock valued at $263,000 after buying an additional 85 shares in the last quarter. Finally, Naples Global Advisors LLC lifted its stake in shares of Quest Diagnostics by 1.5% during the 4th quarter. Naples Global Advisors LLC now owns 6,171 shares of the medical research company’s stock valued at $851,000 after buying an additional 90 shares in the last quarter. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.